NLS Pharmaceutics Ltd.
13F holders, Q3 2024 (September 30)2holders
$5.07avg. 13F price*
At the end of Q3 2024, 2 institutions reported holding NLS Pharmaceutics Ltd. in their 13F filings. The largest holders were BVF Inc. ($728K) and UBS Group AG ($24K).
- Company
- NLS Pharmaceutics Ltd.
- CUSIP
- H57830137
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $752K |
| Exits | 0 | $0 |
Ownership 2 holders
| BVF Inc. | 0.02% | New | 143,676 | $728K |
| UBS Group AG | 0.00% | New | 4,719 | $24K |
"% of holder's portfolio" is NLS PHARMACEUTICS LTD's weight in each manager's 13F, not the share of NLS Pharmaceutics Ltd. the manager owns.